Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.

Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I, McAllister SS.

Breast Cancer Res. 2017 Mar 6;19(1):23. doi: 10.1186/s13058-017-0815-8.

2.

SEOM Clinical Guideline for bone metastases from solid tumours (2016).

Grávalos C, Rodríguez C, Sabino A, Seguí MÁ, Virizuela JA, Carmona A, Cassinello J, Isla D, Jara C, Martín M.

Clin Transl Oncol. 2016 Dec;18(12):1243-1253. Epub 2016 Nov 28.

3.

Immune modulation of CD4+CD25+ regulatory T cells by zoledronic acid.

Liu H, Wang SH, Chen SC, Chen CY, Lo JL, Lin TM.

BMC Immunol. 2016 Nov 25;17(1):45.

4.

Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting.

Seber S, Solmaz D, Yetisyigit T.

Onco Targets Ther. 2016 Aug 9;9:4929-35. doi: 10.2147/OTT.S108968. eCollection 2016.

5.

Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.

Drieling RL, LaCroix AZ, Beresford SA, Boudreau DM, Kooperberg C, Chlebowski RT, Gass M, Crandall CJ, Womack CR, Heckbert SR.

Menopause. 2016 Nov;23(11):1168-1175.

PMID:
27433859
6.

Novel ERα positive breast cancer model with estrogen independent growth in the bone microenvironment.

Capietto AH, Chan SR, Ricci B, Allen JA, Su X, Novack DV, Schreiber RD, Faccio R.

Oncotarget. 2016 Aug 2;7(31):49751-49764. doi: 10.18632/oncotarget.10443.

7.

Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer.

Moon PG, Lee JE, Cho YE, Lee SJ, Chae YS, Jung JH, Kim IS, Park HY, Baek MC.

Oncotarget. 2016 Jun 28;7(26):40189-40199. doi: 10.18632/oncotarget.9561.

8.

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?

Kasimir-Bauer S, Reiter K, Aktas B, Bittner AK, Weber S, Keller T, Kimmig R, Hoffmann O.

Sci Rep. 2016 May 23;6:26355. doi: 10.1038/srep26355.

9.

The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.

Kim HA, Ahn SH, Nam SJ, Park S, Ro J, Im SA, Jung YS, Yoon JH, Hur MH, Choi YJ, Lee SJ, Jeong J, Cho SH, Kim SY, Lee MH, Kim LS, Moon BI, Kim TH, Park C, Kim SJ, Jung SH, Park H, Gwak GH, Kang SH, Kim JG, Kim J, Choi SY, Lim CW, Kim D, Yoo Y, Song YJ, Kang YJ, Jung SS, Shin HJ, Lee KJ, Han SH, Lee ES, Han W, Kim HJ, Noh WC.

BMC Cancer. 2016 May 19;16:319. doi: 10.1186/s12885-016-2354-6.

10.

Adjuvant endocrine therapy in premenopausal women with breast cancer.

Kadakia KC, Henry NL.

Clin Adv Hematol Oncol. 2015 Oct;13(10):663-72.

11.

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.

Ma RM, Chen CZ, Zhang W, You J, Huang DP, Guo GL.

Medicine (Baltimore). 2016 Mar;95(13):e3240. doi: 10.1097/MD.0000000000003240.

12.

Does estrogen play a role in response to adjuvant bone-targeted therapies?

Russell K, Amir E, Paterson A, Josse R, Addison C, Kuchuk I, Clemons M.

J Bone Oncol. 2013 Jul 5;2(4):167-73. doi: 10.1016/j.jbo.2013.06.001. eCollection 2013 Dec. Review.

13.

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials.

Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ.

J Bone Oncol. 2013 Feb 9;2(2):70-6. doi: 10.1016/j.jbo.2013.01.002. eCollection 2013 Jun.

14.

The role of the bone microenvironment in skeletal metastasis.

Zheng Y, Zhou H, Dunstan CR, Sutherland RL, Seibel MJ.

J Bone Oncol. 2012 Dec 11;2(1):47-57. doi: 10.1016/j.jbo.2012.11.002. eCollection 2013 Feb. Review.

15.

A national portfolio of bone oncology trials-The Canadian experience in 2012.

Kuchuk I, Simos D, Addison CL, Clemons M.

J Bone Oncol. 2012 Oct 17;1(3):95-100. doi: 10.1016/j.jbo.2012.09.001. eCollection 2012 Dec. Review.

16.

Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?

Russell K, Clemons M, Costa L, Addison CL.

J Bone Oncol. 2012 May 24;1(1):12-7. doi: 10.1016/j.jbo.2012.04.003. eCollection 2012 Jun. Review.

17.

Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.

Simone V, D'Avenia M, Argentiero A, Felici C, Rizzo FM, De Pergola G, Silvestris F.

Oncologist. 2016 Apr;21(4):404-17. doi: 10.1634/theoncologist.2015-0351. Epub 2016 Feb 10.

18.

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives.

Barroso-Sousa R, Silva DD, Alessi JV, Mano MS.

Ecancermedicalscience. 2016 Jan 7;10:609. doi: 10.3332/ecancer.2016.609. eCollection 2016. Review.

19.

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.

Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE.

J Natl Cancer Inst. 2016 Jan 12;108(4). pii: djv360. doi: 10.1093/jnci/djv360. Print 2016 Apr. Erratum in: J Natl Cancer Inst. 2016 Mar;108(3). pii: djw017. doi: 10.1093/jnci/djw017.

20.

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.

Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JW, Kohno N.

Eur J Cancer. 2016 Feb;54:57-63. doi: 10.1016/j.ejca.2015.10.011. Epub 2015 Dec 23.

Supplemental Content

Support Center